100,000 euros to be used in pilot projects for solutions for dementia
Lisbon, April 13, 2022 – Roche will announce on the 30th of April the ‘startups’ that will receive a grant to apply digital solutions and services in the area of dementia in Portuguese healthcare facilities, for a total of 100 thousand euros.
There were about 100 national and international ‘startups’ that applied with pilot projects for solutions with real and immediate impact in the area of dementia. Building Tomorrow Together – Innovation in Dementia is the name of the new initiative that brings together several entities in the health sector in Portugal to develop solutions capable of bringing more quality of life to people with dementia and Alzheimer’s Disease.
Of all the candidates, 25 projects were selected to make a more detailed presentation to the initiative’s partners.
On April 30, the projects that will be implemented as pilots in Portuguese healthcare facilities will be announced, in a session that will take place at Roche’s headquarters, in Amadora, and which will be broadcast online at roche.pt and on Roche Portugal’s Facebook.
In addition to Roche, which started the initiative, the following entities are partners in this project: Hospital de São João, Centro Hospitalar de Entre o Douro e Vouga, Luz Saúde, Hospital Lusíadas, CUF and the Senior Neurological Campus, as well as such as Multicare, Microsoft, EIT Health, BIAL, AWS, Fundação Calouste Gulbenkian, Fundação Champalimaud, Alzheimer Portugal and NOS.
Until September 2022, the ‘startups’ will be focused on working on solutions adapted to three key challenges previously established by the partners:
? education and disease prevention, namely solutions that combat the stigma surrounding Dementia and that help prepare society to prevent, detect and deal with the disease;
? early and improved diagnosis, focusing on technologies that allow earlier but also better diagnosis: less invasively, faster and more effectively, but also more comprehensively, evaluating the patient for personalized and humane care;
? disease management and support for patients and caregivers, with a focus on tools that support patients and families to live with and manage the disease and help teams provide integrated care around the patient.
In September, each designed solution will then be tested in the real context and presented to the Health ecosystem.
After the first year of action, Building Tomorrow Together – Innovation in Dementia has a five-year ambition in which it intends to evolve and bring together new entities in the health sector.
Considering that the proportion of elderly people in the population is increasing in almost all countries, the number of people suffering from dementia is expected to increase to 78 million in 2030 and 139 million in 2050, according to data from the World Health Organization (WHO). . In this field, Alzheimer’s disease is the most common form of dementia and can be challenging to diagnose at an early stage. Data from the Alzheimer Europe Report show that there are around 46 million people with Alzheimer’s in the world. In Portugal, there were about 194,000 cases of dementia, with a predominance of Alzheimer’s disease, in 2018 – a number that is expected to double in the coming years.
See the attached program for the April 30th session.
The Roche group has been present in Portugal since 1973 and currently has employees in the Pharmaceuticals and Diagnostics divisions, which includes the Diabetes Care area. Roche is a global company, pioneer in the development of pharmaceutical products and diagnostic systems, which aim to advance science and improve people’s lives. Roche offers innovative solutions for both pharmaceuticals and diagnostics, positioning itself as a leader in personalized healthcare – an approach that aims to tailor the right treatment to each patient in the best possible way.
Roche is the world’s largest biotechnology company with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and central nervous system diseases. Roche is also a world leader in in vitro diagnostics and a pioneer in diabetes management.
For more information, visit www.roche.com or www.roche.pt